Role of PET/CT in carcinoma Gallbladder Management

Posted by Dr. Rutuja Kote on Wed, Dec 14, 2022

Brief Introduction:

  • Aggressive and lethal malignancy
  • 6th most common GI malignancy
  • Advanced disease at diagnosis
  • 80% metastatic at diagnosis
  • 20% resectable

Risk Factors:

  • Women>Men
  • Older age group
  • Cholelithiasis
  • Smoking
  • Salmonella typhi infection- bile carcinogens
  • Porcelain Gallbladder

Investigations:

  • CT/MRI - not able to differentiate between scarring and residual tumor.

Radiographic features:

  • Mass replacing gall bladder - hypoattenuating/isoattenuating mass in gall bladder fossa- leading to biliary obstruction.

  • Wall thickening- usually > 1cm. Mimics benign conditions.

  • Intraluminal polypoid.

Extension of tumor

  • The most common direct extension is - Liver, followed by colon, followed by the duodenum, and followed by the pancreas.

Role of 18F FDG PET/CT in the management of carcinoma gallbladder:

In diagnosis:

Image

  • Detection of residual disease in those patients who underwent Cholecystectomy for a benign cause.
  • NCCN still doesn’t recommend PET/CT routinely for pre-op workup or response assessment in a carcinoma gall bladder patients but recognises promising results in studies.

Staging:

  • To rule out hepatic and extrahepatic metastasis.
  • It is not a good method to detect carcinomatosis, especially in small volumes of tumors.
  • Signet ring variant of tumor Show variable FDG uptake. Therefore FDG is not ideal for staging in those tumors.

Image

  • Leung et al, found that 18F FDG PET/CT has added value as an addition to CT and helps confirm suspicious nodal disease.
  • Butte et al, showed that 18F FDG PET/CT has value in staging in patients with T1b or greater stage of tumour and it is better in detecting lymph nodes compared to CT alone.
  • Petrowsky et al, showed that 18F FDG PET/CT is superior to CT alone in identifying distant metastases.

Therapeutic decisions:

  • FDG PET/CT upstages patients, which leads to a change in the management of the patients.
  • It identifies disseminated disease- and prevents aggressive curative attempts.
  • Hwang et al, showed that SUVmax from PET/CT is an independent predictor of OS.
  • Yoo et al, showed that TLG - a volume based metabolic parameter is predictive of PS and superior to both MTV and SUV.